IRIS Institutional Research Information System - OPENBS Open Archive UniBS

CATTANEO, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.429
AS - Asia 3.151
EU - Europa 2.767
SA - Sud America 587
Continente sconosciuto - Info sul continente non disponibili 76
AF - Africa 67
OC - Oceania 7
Totale 12.084
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.315
CN - Cina 1.278
SG - Singapore 995
UA - Ucraina 774
DE - Germania 530
BR - Brasile 479
IT - Italia 463
HK - Hong Kong 322
FR - Francia 235
FI - Finlandia 186
VN - Vietnam 178
GB - Regno Unito 159
RU - Federazione Russa 151
TR - Turchia 119
IE - Irlanda 110
IN - India 72
BD - Bangladesh 63
CA - Canada 57
AR - Argentina 42
ZA - Sudafrica 32
MX - Messico 28
SE - Svezia 28
PL - Polonia 24
EC - Ecuador 22
IQ - Iraq 22
NL - Olanda 19
JP - Giappone 18
BE - Belgio 17
ES - Italia 17
CO - Colombia 13
PK - Pakistan 13
ID - Indonesia 12
LT - Lituania 11
AT - Austria 10
EU - Europa 10
PY - Paraguay 8
UZ - Uzbekistan 8
VE - Venezuela 8
CL - Cile 7
JM - Giamaica 7
AE - Emirati Arabi Uniti 6
AU - Australia 6
DZ - Algeria 6
NG - Nigeria 6
AZ - Azerbaigian 5
IL - Israele 5
MA - Marocco 5
PA - Panama 5
SA - Arabia Saudita 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
AL - Albania 4
KE - Kenya 4
PH - Filippine 4
RS - Serbia 4
TN - Tunisia 4
EG - Egitto 3
IR - Iran 3
LB - Libano 3
MK - Macedonia 3
MU - Mauritius 3
AM - Armenia 2
BO - Bolivia 2
BY - Bielorussia 2
CH - Svizzera 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
GT - Guatemala 2
HU - Ungheria 2
JO - Giordania 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LU - Lussemburgo 2
LV - Lettonia 2
NI - Nicaragua 2
NP - Nepal 2
RO - Romania 2
TH - Thailandia 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
CI - Costa d'Avorio 1
CM - Camerun 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
GE - Georgia 1
GI - Gibilterra 1
HN - Honduras 1
HR - Croazia 1
IS - Islanda 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
MN - Mongolia 1
MQ - Martinica 1
MT - Malta 1
Totale 12.012
Salva come PNG Salva come JPEG
Città #
Jacksonville 536
Singapore 492
Fairfield 447
Woodbridge 422
Ashburn 371
Hong Kong 322
Houston 307
Beijing 276
Ann Arbor 239
San Jose 233
The Dalles 221
Princeton 213
Cambridge 209
Nanjing 198
Wilmington 198
Seattle 173
Chandler 143
New York 120
Columbus 117
Dublin 110
Los Angeles 99
Istanbul 97
Lauterbourg 92
Helsinki 79
Nanchang 70
Milan 69
Ho Chi Minh City 63
Moscow 59
Des Moines 57
Hebei 57
Buffalo 53
Changsha 45
Shenyang 45
Hanoi 42
São Paulo 40
Dallas 38
Council Bluffs 36
San Diego 36
Kunming 34
Shanghai 33
Tianjin 32
Jiaxing 31
Lancaster 31
Jinan 28
Munich 28
San Francisco 28
Santa Clara 23
Rome 22
Orem 21
Redondo Beach 21
Toronto 21
Brooklyn 19
Charlotte 18
Chicago 18
Atlanta 17
Brussels 17
Hangzhou 17
Johannesburg 16
London 16
Rio de Janeiro 16
Tokyo 16
Mexico City 15
Nürnberg 15
Verona 15
Warsaw 15
Zhengzhou 15
Brescia 13
Haikou 12
San Mateo 12
Chennai 11
Lanzhou 11
Augusta 10
Belo Horizonte 10
Dearborn 10
Dhaka 10
Guayaquil 10
Kocaeli 10
Miami 10
Monmouth Junction 10
Ningbo 10
Phoenix 10
Curitiba 9
Frankfurt am Main 9
Guangzhou 9
Montreal 9
Taiyuan 9
Trieste 9
Da Nang 8
Denver 8
Taizhou 8
Turku 8
Vienna 8
Amsterdam 7
Baghdad 7
Boston 7
Brasília 7
Fuzhou 7
Genoa 7
Haiphong 7
Itajaí 7
Totale 7.331
Salva come PNG Salva come JPEG
Nome #
Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. 220
SINDROME DA ANTICORPI ANTIFOSFOLIPIDI E LESIONI PUNTIFORMI DELLA SOSTANZA BIANCA ALLA RISONANZA MAGNETICA. QUAL E' IL LORO SIGNIFICATO? VALUTAZIONE DI 169 PAZIENTI CON MANIFESTAZIONI NEUROLOGICHE 209
Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS). 197
Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. 168
Desensibilizzazione orale alla rifampicina: descrizione di un nuovo protocollo. 163
CD3-CD4+ cells with a Th2-like pattern of cytokine production in the peripheral blood of a patient with cutaneous T cell lymphoma. 162
In vitro cell death of activated lymphocytes in Omenn's syndrome 158
[Neonatal lupus: clinical features and risk of congenital cardiac heart block in newborns from mothers with anti Ro/SSA antibodies] 156
Expression of CD28 on CD8+ and CD4+ Lymphocytes During HIV Infection 154
Studio con TC ad alta risoluzione (HRCT) dell’interstizio polmonare in alcune malattie autoimmunitarie sistemiche. 150
Antiphospholipid antibody profile: implications for the evaluation and management of patients. 150
Discordance for systemic lupus erythematosus and hyper IgE syndrome in a pair of monozygotic twins 150
Antiphospholipid antibody: laboratory, pathogenesis and clinical manifestations 147
Idiopathic eosinophilic pneumonia and pregnancy: report of a case. 139
Esposizione a latice nelle aziende sanitarie: esperienze pratiche 137
Circulating immune complexes in human acute leukaemia. 137
I polimorfismi della metilentetraidrofolatoreduttasi (MTHFR) nel trattamento con methotrexate di pazienti con artrite reumatoide. Revisione della letteratura ed esperienza personale. 136
Inhibitory effect of IgM rheumatoid factor on immune complex solubilization capacity and inhibition of immune precipitation. 133
IL COMPLEMENTO NELLA GRAVIDANZA DI DONNE AFFETTE DA SINDROME DA ANTICORPI ANTIFOSFOLIPIDI PRIMARIA 132
[TNF-alpha inhibition in anti-Ro/SSA positive patients with rheumatoid arthritis: clinical and immunologic effects] 132
Deforming arthropathy of the hands in Systemic Lupus Erythematosus is associated with antibodies to SS-A/Ro and to SS-B/La. 130
Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. 130
Prevenzione delle reazioni allergiche in pazienti sensibilizzati a latice 128
Upregulation of myxovirus-resistance protein A: a possible marker of type I interferon induction in systemic sclerosis. 128
Anti beta2-glycoprotein I antibodies: clinical significance. 128
ANTI-RNA POLYMERASE III ANTIBODIES AS A RISK MARKER FOR EARLY DEVELOPMENT OF GASTRIC ANTRAL VASCULAR ECTASIA IN SYSTEMIC SCLEROSIS 127
Antiperinuclear factor in psoriatic arthropathy 125
Oesophageal manometry in early and definite systemic sclerosis. 125
Antinuclear antibodies in psoriatic arthritis and its subgroups 123
Nonorgan specific autoantibodies and heart damage. 123
Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients 123
LUPUS ERITEMATOSO SISTEMICO AD ESORDIO TARDIVO: CARATTERISTICHE CLINICHE ED IMMUNOLOGICHE 122
Anti-Ku antibodies in connective tissue disease: clinical and serologic evaluation of 14 patients. 120
AUMENTO DELLA PROTEINA C-REATTIVA, ANTICORPI ANTI-CCP E FATTORE REUMATOIDE NELL'ARTRITE LUPICA 119
Electrocardiographic abnormalities in infants born from mothers with autoimmune diseases: a multicentre prospective study. 118
Antiphospholipid antibodies and malignancies 117
EVALUATION OF NEUROLOGICAL MANIFESTATIONS IN 180 PATIENTS (PTS) WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME (PAPS) 117
Defective expression of HLA class I and CD1a molecules in boy with Marfan-like phenotype and deep skin ulcers 117
The immune development in a child born to a cyclosporin A-treated woman with systemic lupus erythematosus/polymyositis 116
Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. 116
Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. 116
Anticorpi antinucleo e artrite psoriasica 116
Pregnancy in systemic sclerosis: a prospective study 116
ANTICORPI ANTI-SU NELLA SINDROME DA ANTICORPI ANTI-FOSFOLIPIDI PRIMARIA (PAPS) 116
Immune reconstitution after bone marrow transplantation for combined immunodeficiencies: down modulation of Bcl-2 and high expression of CD95/Fas account for increased susceptibility to spontaneous and activation-induced lymphocyte cell-death 115
Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients 115
Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations. 115
The anti-beta-2 glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species' evolution. 114
Vasculite orticarioide: valutazione clinica, laboratoristica e terapeutica di 17 pazienti. 114
Anti-Ro/SSA autoantibodies over time in mothers of children with congenital complete heart block. 114
SINDROME DA ANTICORPI ANTIFOSFOLIPIDI PRIMARIA: FOCUS SULLE MANIFESTAZIONI NEUROLOGICHE 114
RELATIONSHIP BETWEEN SLE SUSCEPTIBILITY GENES AND CLINICAL MANIFESTATIONS IN A COHORT OF PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME 114
SINDROME DA ANTICORPI ANTIFOSFOLIPIDI PRIMARIA E LUPUS ERITEMATOSO SISTEMICO: DIFFERENZE E SOMIGLIANZE GENETIHE 113
Role of anti-prothrombin in antiphospholipid syndrome. 112
Antiphospholipid and anti beta 2 glycoprotein I antibodies in patients with obstetrical complications 111
MANIFESTAZIONI NEUROLOGICHE IN 180 PAZIENTI CON SINDROME DA ANTICORPI ANTIFOSFOLIPIDI PRIMARIA. RUOLO DEI FATTORI DI RISCHIO CARDIOVASCOLARI 110
Clinical and serological features of 35 patients with anti-Ki autoantibodies. 109
More on anticardiolipin and anti-beta2 glycoprotein I in systemic sclerosis. 109
Chilblain Lupus Erythematosus (CL) è associato ad anticorpi anti SSA/Ro 109
Systemic lupus erythematosus and pregnancy: a prospective study. 108
Antinuclear antibodies and psoriatic arthritis 107
NEUROLOGICAL MANIFESTATIONS IN 169 PATIENTS WITH PAPS: WHICH SIGNIFICANCE FOR SMALL HYPERINTENSE WHITE MATTER LESIONS AT MAGNETIC RESONANCE IMAGING? 107
IL "PROFILO" DEGLI ANTICORPI ANTIFOSFOLIPIDI NELLA SINDROME PRIMARIA COME FATTORE DI RISCHIO PER EVENTI CLINICI: STUDIO DI 175 PAZIENTI 107
Proliferazioni di cloni di tipo Th2 con fenotipo CD3- CD4+. Studio di 2 casi. 105
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of Low-dose versus high-dose intravenous cyclophosphamide. 105
Anti-Ro/SSA antibodies in rheumatoid arthritis: clinical and immunologic associations. 104
Esophageal Dysfunction in Patients with Definite and Early Systemic Sclerosis 103
ANTICORPI ANTIFOSFOLIPIDI E NEOPLASIE (aPL E NEOPLASIE) 103
Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients. 102
PREGNANCY OUTCOMES IN WOMEN EXPOSED TO BIOLOGIC TREATMENT AND AFFECTED BY CHRONIC ARTHRITIS 100
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. 99
Anti-TNFalpha treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies. 99
Intravenous immunoglobulin in pregnancy: a chance for patients with an autoimmune disease. 97
Decreased number of peripheral blood CD4 + CD29+ lymphocytes and increased in vitro spontaneous production of anti-DNA antibodies in patients with active systemic lupus erythematosus. 97
Lymphadenopathic and oropharyngeal Kaposi's sarcoma in a drug addict with acquired immunodeficiency syndrome. Immunological abnormalities in peripheral blood and lymphoid tissue 97
Undifferentiated connective tissue disease with antibodies to Ro/SSA: clinical features and follow-up of 148 patients 97
IL METHOTREXATE (MTX) E I GENOTIPI DELLA METILENTETRAIDROFOLATOREDUTTASI (MTHFR) NEL TRATTAMENTO DI PAZIENTI ITALIANI CON MALATTIE REUMATICHE 96
CONNETTIVITE INDIFFERENZIATA (UCTD) DI RECENTE DIAGNOSI: PROFILO CLINICO ED IMMUNOLOGICO 96
The neonatal lupus erythematosus associated with isolated LA(SSB) antibodies. 96
[A high-resolution computed tomographic study of the pulmonary interstitium in systemic autoimmune diseases] Studio con tomografia computerizzata con alta risoluzione dell’interstizio polmonare in alcune malattie autoimmunitarie sistemiche. 94
Chillblain lupus erythematosus is associated with antibodies to SSA/Ro 94
Isotype switching and titer variation of anti-Ro/SSA antibodies over time in 100 patients with undifferentiated connective tissue disease (UCTD). 92
Antiperinuclear factor (APF) in patients with psoriasic arthtritis 90
L'orticaria. 89
Induction of experimental SLE in naive mice by immunization with human polyclonal anti-DNA antibody carrying the 16/6 idiotype. 89
Chilblain Lupus Erythematosus (CL) is associated with antibodies SSA/Ro 88
Oesophageal dysfunction in patients with definite and early systemic sclerosis 88
Esofagopatia sclerodermia in pazienti con sclerosi sistemica (SSC) “precoce” secondo Le Roy-Mesdger: confronto con altri subset di malattia. Studio clinico-manometrico di 181 pazienti 87
TERAPIE BIOLOGICHE E GRAVIDANZA: RISULTATI DI UNO STUDIO MULTICENTRICO ITALIANO 87
Chronic urticaria induced by eradication therapy of Helicobacter pilori: a case report. 86
Anti-TNFalpha agents in elderly patients with rheumatoid arthritis: a study of a group of 105 over sixty five years old patients 85
Lessons from the "Euro-Lupus Cohort". 85
Discordance for Systemic LupusErythematosus and Hyper IgE Syndrome in a pair of monozygous twins 84
Pretransplant antitumor conditioning (fTBI dose) correlates with bone marrow histology at day 0 in leukemic patients. 84
LA RIDUZIONE DEL NUMERO ASSOLUTO DELLE CELLULE T CD8+CD28- CIRCOLANTI ENTRO 6 MESI DI TERAPIA CON ABATACEPT COME FATTORE PREDDITIVO DI BUONA RISPOSTA CLINICA A 1 ANNO 84
European Working Party on Systemic Lupus Erythematosus. Lessons from the "Euro-Lupus Cohort". 80
European Working Party on Systemic Lupus Erythematosus. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". 79
Five-year follow-up of 165 Italian patients with undifferentiated connective tissue diseases 77
Antiphospholipid antibodies and intestinal pathology 76
Lupus neonatale: manifestazioni cliniche e rischio di blocco cardiaco congenito in neonati da madri con anticorpi anti-Ro/SSA. 75
Totale 11.552
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.944
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.944
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022734 0 152 14 56 12 27 22 56 39 87 70 199
2022/2023576 113 5 5 20 58 173 3 54 96 3 16 30
2023/2024630 53 19 41 31 13 102 21 23 216 3 1 107
2024/20251.500 2 7 5 177 218 116 99 52 149 127 362 186
2025/20263.188 345 503 245 515 305 192 421 125 162 245 88 42
2026/2027257 196 61 0 0 0 0 0 0 0 0 0 0
Totale 12.084